RE: Capital gains haleon glaxo17 Jul 2022 10:21
Chargeable gains
Shareholders who are resident in the UK for UK tax purposes should not be treated, by
virtue of the receipt of Haleon Shares pursuant to the Demerger, as making a disposal or
part disposal of their GSK Shares for the purposes of the taxation of chargeable gains.
Instead, the Haleon Shares issued to each such Shareholder pursuant to the Demerger
should be treated as the same asset, and as having been acquired at the same time, as
the GSK Shares already held by them. On this basis, such Shareholders should not incur
any liability to tax on chargeable gains as a result of the Demerger. The aggregate base
cost of the GSK Shares and Haleon Shares immediately after the Demerger should be
the same as the base cost of the GSK Shares immediately before the Demerger. Such
base cost should be apportioned between the GSK Shares and the Haleon Shares held
by each Shareholder by reference to their respective market values on the first day on
which the market values or prices are quoted or published for such shares.
So apportion your original base cost as follows:
Original_base_cost x G/(G+H) for the now GSK portion and
Original_base_cost x H/(G+H) for the now Haleon portion,
where G and H are the respective closing share prices on Monday.